Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $11.36.

A number of research analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Monday, December 9th. Robert W. Baird dropped their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Finally, HC Wainwright restated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in Vor Biopharma during the third quarter valued at $54,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vor Biopharma during the second quarter valued at $63,000. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma during the second quarter worth about $53,000. Finally, Exchange Traded Concepts LLC increased its stake in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after acquiring an additional 48,017 shares during the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Up 2.9 %

VOR opened at $1.02 on Tuesday. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14. The company’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $0.92. The stock has a market cap of $70.04 million, a price-to-earnings ratio of -0.62 and a beta of -0.37.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). As a group, sell-side analysts anticipate that Vor Biopharma will post -1.55 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.